A Phase 2/3 interventional study of Linvoseltamab and Bortezomib in Multiple Myeloma (MM), sponsored by Regeneron Pharmaceuticals. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Regeneron Pharmaceuticals · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing linvoseltamab in Multiple Myeloma — 13 open to participants now, 15 under way, 4 of them phase 3. linvoseltamab · Multiple Myeloma.
Among the 16 studies testing linvoseltamab in Multiple Myeloma, this one is the 16th largest by enrollment, is one of 7 that started in 2026, is the only one in phase 2/3, and was the 15th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →13 of the 16 studies testing linvoseltamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Medical College of Wisconsin · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, France, Japan and 3 more countries
Ages 18+
Multiple Myeloma Research Consortium · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
linvoseltamab: first FDA approval 2025 (LYNOZYFIC), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 5 · Phase 4 1
First in 2019; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 168 across the 16 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 6 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
15 studies in Multiple Myeloma by Regeneron Pharmaceuticals: 9 open now, 11 under way, 3 of them phase 3. Of 2 finished, 0 (0%) have results posted.
Among the 15 studies in Multiple Myeloma by Regeneron Pharmaceuticals, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2026, is the only one in phase 2/3, and was the 13th registered.
Regeneron Pharmaceuticals’s Multiple Myeloma studies by the year they started, since 2019.
2 of the studies testing linvoseltamab in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06376526Dickran Kazandjian, MDIMMUNOPLANT for Newly Diagnosed Multiple Myeloma | 2027-08-31 |
| NCT07609940Regeneron PharmaceuticalsAdult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) | 2027-10-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing linvoseltamab in Multiple Myeloma, from their registry updates:
Among Regeneron Pharmaceuticals’s 15 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is focused on participants with Newly Diagnosed Multiple Myeloma (NDMM) who are eligible for high dose chemotherapy followed by Autologous Stem Cell Transplantation (ASCT).
This study is evaluating a drug called linvoseltamab in combination with standard therapies for multiple myeloma called bortezomib (V) and lenalidomide (R). This combination is abbreviated as Linvo-VR.
The aim of this study is to compare how well Linvo-VR, with and without ASCT, treats myeloma to how well the current standard of care regimen for NDMM treats myeloma. That current standard of care regimen includes the drugs daratumumab (D), bortezomib (V), lenalidomide (R), and dexamethasone (d). This combination is referred to as DVRd. The study is also evaluating if Linvo-VR treats myeloma well enough that ASCT is no longer needed with the first myeloma treatments.
The study is looking at several other research questions, including:
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Linvoseltamab · Drug: Bortezomib · Drug: Lenalidomide
Drug: Linvoseltamab · Drug: Bortezomib · Drug: Lenalidomide
Drug: Bortezomib · Drug: Lenalidomide · Drug: Daratumumab · Drug: Dexamethasone
Administered per the protocol
Also known as: REGN5458, Lynozyfic™
Administered per the protocol
Also known as: Velcade®
Administered per the protocol
Also known as: Revlimid®
Administered per the protocol
Also known as: Darzalex Faspro®,, Darzalex®
Administered per the protocol
Also known as: Dexahexal®,, Decadron®
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Phase 2
Time frame: Up to day 112
Severity of TEAEs
Phase 2
Time frame: Up to day 112
Achievement of Complete Response or better (≥CR) per International Myeloma Working Group (IMWG) criteria
Phase 2
Time frame: Up to day 112
Minimal Residual Disease (MRD) negative CR at 10^-5 per IMWG criteria
Phase 3
Time frame: Up to 12 months
Progression Free Survival (PFS) per IMWG
Phase 3
Time frame: Up to 5 years
Occurrence of TEAEs
Phase 2
Time frame: Up to 3.5 years
Severity of TEAEs
Phase 2
Time frame: Up to 3.5 years
Occurrence of Serious Adverse Events (SAEs)
Phase 2
Time frame: Up to 3.5 years
Severity of SAEs
Phase 2
Time frame: Up to 3.5 years
Occurrence of Cytokine Release Syndrome (CRS)
Phase 2
Time frame: Up to day 30
Severity of CRS
Phase 2
Time frame: Up to day 30
Occurrence of Cell-Associated Neurotoxicity Syndrome (ICANS)
Phase 2
Time frame: Up to day 30
Severity of ICANS
Phase 2
Time frame: Up to day 30
Achievement of objective response [Partial Response or better (≥PR)] per IMWG criteria
Time frame: Up to 5 years
Time to ≥PR per IMWG criteria
Time frame: Up to 5 years
Time to Very Good Partial Response or better (≥VGPR) per IMWG criteria
Time frame: Up to 5 years
Time to ≥CR per IMWG criteria
Time frame: Up to 5 years
Achievement of MRD negative (at 10^-5 sensitivity) CR per IMWG criteria
Time frame: Up to 5 years
Duration Of Response (DOR) of ≥PR per IMWG criteria
Time frame: Up to 5 years
Duration of ≥VGPR per IMWG criteria
Time frame: Up to 5 years
Duration of ≥CR per IMWG criteria
Time frame: Up to 5 years
PFS per IMWG criteria
Time frame: Up to 5 years
Second PFS (PFS2) per IMWG criteria
Time frame: Up to 5 years
Overall Survival (OS)
Time frame: Up to 5 years
Concentrations of total linvoseltamab in serum
Time frame: Up to 5 years
Occurrence of TEAEs
Phase 3
Time frame: Up to 5 years
Severity of TEAEs
Phase 3
Time frame: Up to 5 years
Occurrence of SAEs
Phase 3
Time frame: Up to 5 years
Severity of SAEs
Phase 3
Time frame: Up to 5 years
Occurrence of second primary malignancies
Phase 3
Time frame: Up to 5 years
Change from baseline in Global Health Status (GHS) per European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30)
Phase 3 The EORTC QLQ-C30 is a 30-item validated questionnaire developed to measure patient-reported Quality of Life (QoL). For GHS, scores range from 1 = "very poor" to 5 = "excellent" with higher scores indicating better functioning and positive changes from baseline indicate improvement.
Time frame: Up to 5 years
Change from baseline in physical functioning per EORTC QLQ-C30
Phase 3 The EORTC QLQ-C30 is a validated 30-item questionnaire designed to measure patient-reported quality of life. Physical functioning is scored from 1 'very poor' to 5 'excellent,' with higher scores indicating better functioning; positive changes from baseline indicate improvement.
Time frame: Up to 5 years
Change from baseline in role functioning per EORTC QLQ-C30
Phase 3 The EORTC QLQ-C30 is a validated 30-item questionnaire designed to measure patient-reported quality of life. Role functioning is scored from 1 'very poor' to 5 'excellent,' with higher scores indicating better functioning; positive changes from baseline indicate improvement.
Time frame: Up to 5 years
Change from baseline in pain per EORTC QLQ-C30
Phase 3 The EORTC QLQ-C30 is a validated 30-item questionnaire designed to measure patient-reported quality of life. Pain is scored from 1 = "not at all" to 9 = "very much". Higher scores indicate higher symptom burden.
Time frame: Up to 5 years
Change from baseline in fatigue per EORTC QLQ-C30
Phase 3 The EORTC QLQ-C30 is a validated 30-item questionnaire designed to measure patient-reported quality of life. Fatigue is scored from1 = "not at all" to 9 = "very much". Higher scores indicate higher symptom burden.
Time frame: Up to 5 years
Change from baseline in disease symptoms per EORTC QLQ- Multiple Myeloma Module 20 (MY20)
Phase 3 The EORTC QLQ-MY20 is a self-administered instrument to assess QoL in persons with MM. This 20-item questionnaire includes 6 items for disease symptoms. A high score for a symptom scale/item represents a high level of symptomatic problem.
Time frame: Up to 5 years
Change from baseline in treatment side effects per EORTC QLQ-MY20
Phase 3 The EORTC QLQ-MY20 is a self-administered instrument to assess QoL in persons with MM. This 20-item questionnaire includes 10 items for treatment side effects. A high score for a symptom scale/item represents a high level of symptomatic problem.
Time frame: Up to 5 years
Change from baseline in body image per EORTC QLQ-MY20
Phase 3 The EORTC QLQ-MY20 is a self-administered instrument to assess QoL in persons with MM. This 20-item questionnaire includes 1 item for treatment body image. A high score for a symptom scale/item represents a high level of symptomatic problem.
Time frame: Up to 5 years
Change from baseline in future perspective per EORTC QLQ-MY20
Phase 3 The EORTC QLQ-MY20 is a self-administered instrument to assess QoL in persons with MM. This 20-item questionnaire includes 3 items for treatment future perspective. A high score for a symptom scale/item represents a high level of symptomatic problem.
Time frame: Up to 5 years
Change from baseline in EuroQoL-5 Dimensions 5-Level Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS)
Phase 3 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state".
Time frame: Up to 5 years
Time to definitive deterioration in GHS per EORTC QLQ-C30
Phase 3
Time frame: Up to 5 years
Time to definitive deterioration in physical functioning per EORTC QLQ-C30
Phase 3
Time frame: Up to 5 years
Time to definitive deterioration in role functioning per EORTC QLQ-C30
Phase 3
Time frame: Up to 5 years
Time to definitive deterioration in pain per EORTC QLQ-C30
Phase 3
Time frame: Up to 5 years
Time to definitive deterioration in fatigue per EORTC QLQ-C30
Phase 3
Time frame: Up to 5 years
Time to definitive deterioration in disease symptoms per EORTC QLQ-MY20
Phase 3
Time frame: Up to 5 years
Time to definitive deterioration in treatment side effects per EORTC QLQ-MY20
Phase 3
Time frame: Up to 5 years
Time to definitive deterioration in body image per EORTC QLQ-MY20
Phase 3
Time frame: Up to 5 years
Time to definitive deterioration in future perspective per EORTC QLQ-MY20
Phase 3
Time frame: Up to 5 years
Time to definitive deterioration in EQ-5D-5L VAS
Phase 3
Time frame: Up to 5 years
Time to first improvement in GHS per EORTC QLQ-C30
Phase 3
Time frame: Up to 5 years
Time to first improvement in physical functioning per EORTC QLQ-C30
Phase 3
Time frame: Up to 5 years
Time to first improvement in role functioning per EORTC QLQ-C30
Phase 3
Time frame: Up to 5 years
Time to first improvement in pain per EORTC QLQ-C30
Phase 3
Time frame: Up to 5 years
Time to first improvement in fatigue per EORTC QLQ-C30
Phase 3
Time frame: Up to 5 years
Time to first improvement in disease symptoms per EORTC QLQ-MY20
Phase 3
Time frame: Up to 5 years
Time to first improvement in treatment side effects per EORTC QLQ-MY20
Phase 3
Time frame: Up to 5 years
Time to first improvement in body image per EORTC QLQ-MY20
Phase 3
Time frame: Up to 5 years
Time to first improvement in future perspective per EORTC QLQ-MY20
Phase 3
Time frame: Up to 5 years
Time to first improvement in EQ-5D-5L VAS
Phase 3
Time frame: Up to 5 years
Proportion with clinically meaningful improvement in GHS per EORTC QLQ-C30
Phase 3
Time frame: Up to 5 years
Proportion with clinically meaningful improvement in physical functioning per EORTC QLQ-C30
Phase 3
Time frame: Up to 5 years
Proportion with clinically meaningful improvement in role functioning per EORTC QLQ-C30
Phase 3
Time frame: Up to 5 years
Proportion with clinically meaningful improvement in pain per EORTC QLQ-C30
Phase 3
Time frame: Up to 5 years
Proportion with clinically meaningful improvement in fatigue per EORTC QLQ-C30
Phase 3
Time frame: Up to 5 years
Proportion with clinically meaningful improvement in disease symptoms per EORTC QLQ-MY20
Phase 3
Time frame: Up to 5 years
Proportion with clinically meaningful improvement in treatment side effects per EORTC QLQ-MY20
Phase 3
Time frame: Up to 5 years
Proportion with clinically meaningful improvement in body image per EORTC QLQ-MY20
Phase 3
Time frame: Up to 5 years
Proportion with clinically meaningful improvement in future perspective per EORTC QLQ-MY20
Phase 3
Time frame: Up to 5 years
Proportion of clinically meaningful improvement in EQ-5D-5L VAS
Phase 3
Time frame: Up to 5 years
Mean proportion of time with high side effect bother as measured by Functional Assessment of Cancer Therapy (FACIT)- Item Global Population 5 (GP5)
Phase 3 FACIT-Item GP5 will be used to assess the patient-reported impact of treatment toxicity that uses a single item "I am bothered by side effects of treatment" on a 5-point scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much).
Time frame: Up to 5 years
Proportion of patients with high side effect bother as measured by FACIT- Item GP5
Phase 3
Time frame: Up to 5 years
Occurrence of Anti-Drug Antibody (ADA) to linvoseltamab in serum
Phase 3
Time frame: Up to 5 years
Magnitude of ADA to linvoseltamab in serum
Phase 3
Time frame: Up to 5 years
No study locations are listed for this record.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for May 2038, 143 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linvoseltamab